EndoPredict (EPclin) Shown in Second Study to be More Effective than Oncotype DX® (RS) in Women with Intermediate Risk of Breast Cancer Recurrence
October 26, 2017

Myriad Announces Positive Results for an EndoPredict® Clinical Study at 3rd World Congress on Controversies in Breast Cancer

View News Release

EndoPredict® Receives Positive Coverage Decisions From Medicare and Anthem
August, 17, 2017

Brings Total Coverage to Over 90 Percent of Breast Cancer Patients

View News Release

Myriad Launches the EndoPredict® Test in the United States for Patients with Breast Cancer
March 13, 2017

Second-Generation Test Provides More Accurate 10-Year Recurrence Risk for Patients Diagnosed with ER+ HER2- Early-Stage Breast Cancers

View News Release

The EndoPredict® Test Receives Positive Coverage Decisions from Multiple Blue Cross Blue Shield Affiliate Plans
January 6, 2017

Coverage Decisions Expand Access to More Than 32 Million Patients

View News Release

EndoPredict® Reviewed by Blue Cross Blue Shield Association’s Evidence Street
January 5, 2017

The Level of Evidence for EndoPredict Consistent with that of First-Generation Test

View News Release

The EndoPredict® Test Significantly Outperforms the First-Generation Test in Predicting the Risk of Node-Negative and Node-Positive Breast Cancer Recurrence
December 9, 2016

View News Release

Comprehensive Comparison of Prognostic Signatures for Breast Cancer in TransATAC
December 6-10, 2016 – San Antonio Breast Cancer Symposium

View Presentation

“EPclin (EndoPredict) Markedly Outperformed RS (Oncotype DX®) Across the 10-Year Follow-up Period” in a Large Head-to-Head Breast Cancer Study
July 11, 2016

View News Release

Myriad Acquires Sividon Diagnostics: Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict®
May 31, 2016

View News Release


For more information and content, go to
EndoPredict®